Where is Celemics located?

Celemics is headquartered in Seoul, South Korea.

How many employees does Celemics have?

As of Jun 30, 2026, the latest employee count at Celemics is 30.

Where does Celemics rank among its competitors?

Celemics ranks 141st amongst 1266 active competitors, of which 240 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Guardant Health, which secured $350M in Nov, 2025.

Who are the top competitors of Celemics?

Celemics' top competitors include Guardant Health, Natera and Nanopore Technologies. Among them, Guardant Health secured the most recent funding round in November, 2025.

Celemics - 2026 Company Profile, Funding & Competitors

Celemics is a public company based in Seoul (South Korea), founded in 2010. It operates as a Developer NGS-based material with novel sequencing technologies. The company has 1266 active competitors, including 240 funded and 188 that have exited. Its top competitors include companies like Guardant Health, Natera and Nanopore Technologies.

Company Details

Developer NGS-based material with novel sequencing technologies. The company uses its novel DNA Targeted Sequencing technology which offers clients a personalized approach to genome analysis. The company also provides kits for different sequencing methods and also offers a BRCA testing procedure that analyzes BRCA1 and BRCA2 genes associated with potential risk for breast, ovary, colorectal and endometrial, lung, gastric, and other cancers.

Website: www.celemics.com/
Social
Email ID: *****@celemics.com
Phone Number: +82 **********

Key Metrics

Founded Year

2010

Location

Seoul, South Korea

Stage

Public

Investors

Partners Investment & 5 more

Ranked

141^st among 1266 active competitors

Employee Count

30 as on Jun 30, 2026

Similar Companies

Guardant Health & 1043 more

Exit Details

Public

View Celemics' full profile

Celemics got listed on Aug 21, 2020.

Click here to take a look at Celemics's IPO in detail

Celemics is a funded company. Celemics has 6 institutional investors.

View details of Celemics's funding rounds and investors

Celemics' employee count trend

Celemics has 30 employees as of Jun 26. Here is Celemics's employee count trend over the years:

Uncover Celemics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Celemics include Guardant Health, Natera and Nanopore Technologies. Here is the list of Top 10 competitors of Celemics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	Khosla Ventures, Orbimed & 25 others	79/100
2nd	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Foresite Capital & 17 others	77/100
3rd	Nanopore Technologies 2005, Oxford (United Kingdom), Public	Manufacturer of portable and benchtop devices for real-time DNA sequencing	$1.26B	IP Group, GIC & 91 others	75/100
4th	PacBio 2004, Menlo Park (United States), Public	Developer of instrument systems and software for real-time sequencing of single-molecules	$410M	Deerfield, Maverick Capital & 24 others	72/100
5th	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	72/100
6th	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Deerfield, Google Ventures & 11 others	71/100
7th	Helix 2015, San Francisco (United States), Series E	Provider of a genomic database for clinical research	$435M	DFJ Growth, Kleiner Perkins & 12 others	71/100
8th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Braidwell & 19 others	70/100
9th	Prenetics 2009, Hong Kong (China), Public	Online platform for genetic and diagnostic health testing that helps identify health risks	$67.6M	Beyond Ventures, Ping An Ventures & 21 others	70/100
10th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	69/100
141st	Celemics 2010, Seoul (South Korea), Public	Developer NGS-based material with novel sequencing technologies	-	Partners Investment, Shield Investment & 4 others	38/100